Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Sionna Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Sionna Therapeutics, Inc.’s stock price such as:

• Sionna Therapeutics, Inc.’s current stock price and volume
• Why Sionna Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for SION from analysts
• SION’s stock price momentum as measured by its relative strength

About Sionna Therapeutics, Inc. (SION)

Before we jump into Sionna Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; and SION-719 and SION-451, which are nucleotide-binding domain 1 stabilizers in Phase 1 trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

Want to learn more about Sionna Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Sionna Therapeutics, Inc..

Sionna Therapeutics, Inc.’s Stock Price as of Market Close

As of January 30, 2026, 4:00 PM, CST, Sionna Therapeutics, Inc.’s stock price was $42.260.

Sionna Therapeutics, Inc. is down 0.42% from its previous closing price of $42.440.

During the last market session, Sionna Therapeutics, Inc.’s stock traded between $40.705 and $43.000. Currently, there are approximately 44.26 million shares outstanding for Sionna Therapeutics, Inc..

Sionna Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Sionna Therapeutics, Inc. Stock Price History

Sionna Therapeutics, Inc.’s (SION) price is currently up 2.72% so far this month.

During the month of January, Sionna Therapeutics, Inc.’s stock price has reached a high of $44.190 and a low of $34.625.

Over the last year, Sionna Therapeutics, Inc. has hit prices as high as $45.000 and as low as $7.255. Year to date, Sionna Therapeutics, Inc.’s stock is up 2.72%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Sionna Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of January 30, 2026, there were 0 analysts who downgraded Sionna Therapeutics, Inc.’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Sionna Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Sionna Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Sionna Therapeutics, Inc. (SION) by visiting AAII Stock Evaluator.

Relative Price Strength of Sionna Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of January 30, 2026, Sionna Therapeutics, Inc. has a weighted four-quarter relative price strength of %, which translates to a Momentum Score of and is considered to be NA.

Want to learn more about how Sionna Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Sionna Therapeutics, Inc. Stock Price: Bottom Line

As of January 30, 2026, Sionna Therapeutics, Inc.’s stock price is $42.260, which is down 0.42% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Sionna Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.